A) 3-Hydroxy-2-thiophenecarboxylic acid methyl ester (1, 200 mg, 1 eq.), 4-chlorobenzylchloride (2, 242 mg, 1.2 eq.) and K2CO3 (262 mg, 1.5 eq.) were suspended in methylethylketone (MEK, 4 ml), and refluxed overnight to give 3-[(4-chlorophenyl)methoxy]-2-thiophenecarboxylic acid methyl ester 3 (quantitative yield). The ester 3 was dissolved in THF/MeOH (1:1.25, 4.5 ml) and 2N aq. NaOH (1.66 ml) was added. This solution was stirred for 4 h at 50 °C, giving the free carboxylic acid 4 (282 mg, 95%) after acidification. For amidation, the acid 4 (250 mg) was dissolved in dry DMF (3 ml), and hydroxybenzotriazole (HOBT, 145 mg, 1.15 eq.) and ( 
Supplemental Figure 2.
Metformin does not inhibit the catalytic activity of SHIP2 in cultured hepatoma cells and in liver of db/db mice, but, opposite to kidney, decreases the expression of gluconeogenesis genes. A) Metformin (1 mM) and AS1949490 (10 µM) (20-24h) do not inhibit the catalytic activity of SHIP2 immunoprecipitated from the lysates of hepatoma cells. The catalytic activity of SHIP2 was measured by malachite green phosphate assay. B) Metformin does not inhibit the catalytic activity of SHIP2 in liver of db/db mice. SHIP2 was immunoprecipitated from tissue lysates and its catalytic activity measured by malachite green phosphate assay (n=6-7). C-F) Metformin affects the expression of gluconeogenesis genes. The expression levels of the ratelimiting gluconeogenesis genes PCK1 (C and E) and G6Pase (D and F) in the liver and kidney were analyzed by quantitative RT-PCR (n=6). For quantitative RT-PCR, actin and S18 were used as internal controls for liver and kidney, respectively. The bars show the mean expression in arbitrary units. Data are presented as means ± SD of three independent experiments or as means ± SEM (*P≤0.05, **P≤0.01, Student's t test).
Supplemental Figure 3.
Metformin does not affect the expression level of SHIP2, Akt and glucose transporters in myotubes and podocytes, but activates AMPK in myotubes, podocytes and hepatoma cells in culture. A and B) Metformin has no effect on SHIP2, GLUT1 and GLUT4 expression levels or Akt phosphorylation, but it activates AMPK in L6 myotubes (A) and podocytes (B). AICAR activates AMPK in podocytes (B). Cells were treated with 2 mM metformin or 1 mM AICAR for 20-24 h and lysates were subjected to immunoblot analysis with anti-SHIP2, anti-GLUT1, anti-GLUT4, anti-Akt, anti-pAkt, anti-AMPK, anti-pAMPK, anti-actin and anti-tubulin IgGs. C) Metformin has no effect on SHIP2 expression level, but it activates AMPK in hepatoma cells.
Treatments and immunoblotting were performed as described above. D-P) Quantification of SHIP2 (D, I, O), GLUT1 (E, J) and GLUT4 (F, K) levels in (A, B, C) normalized to either tubulin or actin. Quantification of pAkt (G, L) and pAMPK (H, M, N, P) levels in (A, B, C) presented as pAkt/Akt or pAMPK/AMPK after normalizing to either tubulin or actin. Data are presented as means ± SD of three-four independent experiments (**P≤0.01, ***P≤0.001, Student's t test). Figure 4 . Characterization of L6-GLUT4 cells. A) Expression of HA-GLUT4-GFP in L6-GLUT4 cells visualized by GFP (green color). GFP was used to sort the cells with fluorescence-activated cell sorting according to their HA-GLUT4-GFP expression level to obtain homogenous populations of cells. To visualize the GFP-tag, L6-GLUT4 myoblasts were fixed with 2% paraformaldehyde. B) Surface labeling of L6-GLUT4 cells under basal conditions with anti-HA IgG (red color) visualizing GLUT4 at the plasma membrane. The HA-tag is located in the extracellular domain of GLUT4 and can be used to detect the insertion and exposure of GLUT4 at the cell surface. Scale bar: 50 µm. Infected cells were treated with metformin (2 mM, 20-24 h) and immunoblotting were performed as described above. Data are presented as means ± SD of three-five independent experiments (***P≤0.001, Student's t test). Figure 6 . Metformin does not affect the expression level of SHIP2, Akt, AMPK and glucose transporters in tissues of db/db mice. A and B) Metformin has no effect on SHIP2, GLUT1 and GLUT4 expression levels, or Akt and AMPK phosphorylation in skeletal muscle (A) and kidney (B) of db/db mice. Tissue lysates from metformin-treated and control db/db mice were subjected to immunoblot analysis with anti-SHIP2, ati-GLUT1, anti-GLUT4, anti-Akt, anti-pAkt, anti-AMPK, anti-pAMPK and anti-tubulin IgGs. C) Metformin has no effect on SHIP2 expression level and AMPK phosphorylation in liver. Immunoblotting was performed as described above. D-O) Quantification of SHIP2 (D, I, N), GLUT1 (E, J) and GLUT4 (F, K) expression levels in (A, B, C) normalized to tubulin. Quantification of pAkt (G, L) and pAMPK (H, M, O) levels in (A, B, C) presented as pAkt/Akt and pAMPK/AMPK after normalizing to tubulin. Data are presented as means ± SEM (Student's t test).
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